Collegium Pharmaceutical, Inc - Understand $coll stock

$COLL Market Cap: $1.004 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$599.2M

TTM

Gross Margin

62.39%

TTM

Net Earnings

$88.59M

TTM

Current Assets

$443.8M

Q3 2024

Current Liabilities

$459.4M

Q3 2024

Current Ratio

96.6%

Q3 2024

Total Assets

$1.635B

Q3 2024

Total Liabilities

$1.401B

Q3 2024

Book Value

$234.3M

Q3 2024

Cash

$38.96M

Q3 2024

P/E

11.33

Nov 29, 2024 EST

Free Cash Flow

$192.4M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$566.8M	$463.9M	$276.9M	$310.0M	$296.7M	$280.4M	$28.48M	$1.700M	$0.00	$0.00	$0.00
YoY Change	22.17%	67.56%	-10.69%	4.49%	5.81%	884.73%	1575.06%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$566.8M	$463.9M	$276.9M	$310.0M	$296.7M	$280.4M	$28.48M	$1.700M	$0.00	$0.00	$0.00
Cost Of Revenue	$240.6M	$254.4M	$126.3M	$130.2M	$193.7M	$165.7M	$2.595M	$200.0K
Gross Profit	$326.2M	$209.5M	$150.6M	$179.8M	$103.0M	$114.7M	$25.88M	$1.500M
Gross Profit Margin	57.55%	45.15%	54.4%	58.01%	34.73%	40.92%	90.89%	88.24%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	$159.2M	$172.2M	$119.0M	$113.8M	$116.4M	$126.8M	$92.76M	$80.60M	$18.90M	$2.700M	$1.900M
YoY Change	-7.54%	44.74%	4.5%	-2.25%	-8.13%	36.66%	15.08%	326.46%	600.0%	42.11%
% of Gross Profit	48.81%	82.19%	78.98%	63.3%	113.01%	110.48%	358.39%	5373.33%
Research & Development	$0.00	$3.983M	$9.451M	$9.772M	$10.34M	$8.661M	$8.572M	$14.90M	$8.000M	$15.00M	$14.20M
YoY Change	-100.0%	-57.86%	-3.28%	-5.49%	19.39%	1.04%	-42.47%	86.25%	-46.67%	5.63%
% of Gross Profit	0.0%	1.9%	6.27%	5.43%	10.03%	7.55%	33.12%	993.33%
Depreciation & Amortization	$3.496M	$2.684M	$1.736M	$870.0K	$731.0K	$1.074M	$594.0K	$700.0K	$200.0K	$200.0K	$200.0K
YoY Change	30.25%	54.61%	99.54%	19.02%	-31.94%	80.81%	-15.14%	250.0%	0.0%	0.0%
% of Gross Profit	1.07%	1.28%	1.15%	0.48%	0.71%	0.94%	2.3%	46.67%
Operating Expenses	$159.2M	$176.2M	$133.0M	$123.6M	$126.8M	$135.4M	$101.3M	$95.60M	$26.90M	$17.70M	$16.00M
YoY Change	-9.63%	32.47%	7.59%	-2.51%	-6.37%	33.65%	5.99%	255.39%	51.98%	10.63%
Operating Profit	$167.0M	$33.32M	$17.63M	$56.23M	-$23.75M	-$20.69M	-$75.45M	-$94.10M
YoY Change	401.1%	89.01%	-68.65%	-336.79%	14.81%	-72.58%	-19.82%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Interest Expense	$83.34M	$63.21M	$21.01M	$28.88M	$909.0K	$20.13M	$600.0K	-$100.0K	-$400.0K	-$300.0K	-$200.0K
YoY Change	31.84%	200.81%	-27.24%	3077.34%	-95.48%	3255.0%	-700.0%	-75.0%	33.33%	50.0%
% of Operating Profit	49.92%	189.72%	119.21%	51.36%
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	$75.73M	-$28.85M	-$3.374M	$27.58M	-$22.72M	-$39.13M	-$74.90M	-$94.20M	-$27.30M	-$17.90M	-$16.20M
YoY Change	-362.53%	754.98%	-112.23%	-221.39%	-41.93%	-47.76%	-20.49%	245.05%	52.51%	10.49%
Income Tax	$27.58M	-$3.845M	-$74.89M	$830.0K	$0.00					$0.00	$0.00
% Of Pretax Income	36.41%			3.01%
Net Earnings	$48.16M	-$25.00M	$71.52M	$26.75M	-$22.72M	-$39.13M	-$74.87M	-$94.20M	$4.600M	-$17.90M	-$16.20M
YoY Change	-292.6%	-134.96%	167.33%	-217.74%	-41.93%	-47.74%	-20.53%	-2147.83%	-125.7%	10.49%
Net Earnings / Revenue	8.5%	-5.39%	25.83%	8.63%	-7.66%	-13.95%	-262.91%	-5541.18%
Basic Earnings Per Share	$1.43	-$0.74	$2.05	$0.78	-$0.68	-$1.19
Diluted Earnings Per Share	$1.29	-$0.74	$1.86	$0.76	-$0.68	-$1.19	-$2.472M	-$3.877M	$340.7K	-$908.6K	-$822.3K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Cash & Short-Term Investments	$310.5M	$173.7M	$186.4M	$174.1M	$170.0M	$146.6M	$118.7M	$153.2M	$95.70M	$1.600M	$7.600M
YoY Change	78.8%	-6.83%	7.08%	2.41%	15.96%	23.5%	-22.52%	60.08%	5881.25%	-78.95%
Cash & Equivalents	$238.9M	$173.7M	$186.4M	$174.1M	$170.0M	$146.6M	$118.7M	$153.2M	$95.70M	$1.600M	$7.600M
Short-Term Investments	$71.60M
Other Short-Term Assets	$15.20M	$16.68M	$5.879M	$4.900M	$3.100M	$5.100M	$3.000M	$1.900M	$1.200M	$2.800M	$700.0K
YoY Change	-8.91%	183.74%	19.98%	58.06%	-39.22%	70.0%	57.89%	58.33%	-57.14%	300.0%
Inventory	$32.33M	$46.50M	$17.39M	$15.60M	$9.600M	$7.800M	$1.800M	$1.300M
Prepaid Expenses
Receivables	$179.5M	$183.1M	$105.8M	$83.30M	$73.00M	$77.90M	$10.00M	$2.100M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$537.6M	$420.0M	$315.5M	$277.9M	$255.7M	$237.5M	$133.5M	$158.6M	$96.90M	$4.500M	$8.300M
YoY Change	28.0%	33.1%	13.55%	8.68%	7.66%	77.9%	-15.83%	63.67%	2053.33%	-45.78%
Property, Plant & Equipment	$22.01M	$26.38M	$27.14M	$27.40M	$20.90M	$9.300M	$1.800M	$1.000M	$700.0K	$500.0K	$700.0K
YoY Change	-16.56%	-2.78%	-0.97%	31.1%	124.73%	416.67%	80.0%	42.86%	40.0%	-28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$28.13M	$26.60M	$80.68M	$2.700M	$200.0K	$200.0K	$300.0K	$300.0K	$100.0K	$100.0K	$100.0K
YoY Change	5.77%	-67.03%	2888.0%	1250.0%	0.0%	-33.33%	0.0%	200.0%	0.0%	0.0%
Total Long-Term Assets	$605.7M	$754.1M	$376.5M	$365.9M	$50.60M	$53.70M	$2.100M	$3.400M	$800.0K	$600.0K	$700.0K
YoY Change	-19.68%	100.29%	2.91%	623.12%	-5.77%	2457.14%	-38.24%	325.0%	33.33%	-14.29%
Total Assets	$1.143B	$1.174B	$692.1M	$643.8M	$306.3M	$291.2M	$135.6M	$162.0M	$97.70M	$5.100M	$9.000M
YoY Change
Accounts Payable	$8.692M	$3.494M	$4.189M	$10.00M	$6.200M	$12.20M	$5.700M	$9.100M	$3.500M	$2.200M	$1.200M
YoY Change	148.77%	-16.59%	-58.11%	61.29%	-49.18%	114.04%	-37.36%	160.0%	59.09%	83.33%
Accrued Expenses	$258.7M	$263.4M	$223.8M	$180.1M	$191.7M	$175.3M	$24.30M	$8.900M	$2.200M	$2.000M	$1.000M
YoY Change	-1.76%	17.67%	24.28%	-6.05%	9.36%	621.4%	173.03%	304.55%	10.0%	100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$5.000M	$0.00
YoY Change									-100.0%
Long-Term Debt Due	$183.3M	$162.5M	$48.35M	$47.50M	$3.800M	$1.600M	$1.500M	$2.700M	$2.700M	$1.200M	$300.0K
YoY Change	12.82%	236.07%	1.8%	1150.0%	137.5%	6.67%	-44.44%	0.0%	125.0%	300.0%
Total Short-Term Liabilities	$457.9M	$433.7M	$279.6M	$239.5M	$201.8M	$189.1M	$31.50M	$25.60M	$8.400M	$10.40M	$2.600M
YoY Change	5.58%	55.14%	16.73%	18.68%	6.72%	500.32%	23.05%	204.76%	-19.23%	300.0%
Long-Term Debt	$483.8M	$538.5M	$201.6M	$209.6M	$7.700M	$9.900M	$0.00	$1.500M	$4.200M	$6.900M	$800.0K
YoY Change	-10.14%	167.05%	-3.8%	2622.08%	-22.22%		-100.0%	-64.29%	-39.13%	762.5%
Other Long-Term Liabilities	$6.124M	$7.112M	$7.951M	$8.800M	$9.400M	$700.0K				$0.00	$100.0K
YoY Change	-13.89%	-10.55%	-9.65%	-6.38%	1242.86%					-100.0%
Total Long-Term Liabilities	$490.0M	$545.6M	$209.6M	$218.4M	$17.10M	$10.60M	$0.00	$1.500M	$4.200M	$6.900M	$900.0K
YoY Change	-10.19%	160.31%	-4.04%	1177.19%	61.32%		-100.0%	-64.29%	-39.13%	666.67%
Total Liabilities	$947.9M	$979.3M	$489.1M	$457.8M	$218.9M	$199.7M	$31.50M	$27.10M	$12.60M	$17.30M	$3.500M
YoY Change	-3.21%	100.2%	6.85%	109.14%	9.61%	533.97%	16.24%	115.08%	-27.17%	394.29%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018
Basic Shares Outstanding	33.74M	33.83M	34.94M	34.41M	33.45M	32.95M
Diluted Shares Outstanding	41.79M	33.83M	41.05M	35.15M	33.45M	32.95M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $1.0036 Billion

About COLLEGIUM PHARMACEUTICAL, INC

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 197 full-time employees. The company went IPO on 2015-05-07. The firm commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.

Industry: Pharmaceutical Preparations Peers: Amneal Pharmaceuticals, Inc. ANI PHARMACEUTICALS INC BIODELIVERY SCIENCES INTERNATIONAL INC Edgewise Therapeutics, Inc. NEKTAR THERAPEUTICS JOHNSON & JOHNSON PHIBRO ANIMAL HEALTH CORP Tricida, Inc.